Aligos Therapeutics, Inc. Common Stock (ALGS) — Analysis Summary
Aligos Therapeutics, Inc. Common Stock (ALGS) has a market cap of $39.36M with year-over-year revenue growth of -39.5%. Net margin stands at -1106.7%. The stock trades at a P/E ratio of -0.4.
Key Takeaways
- Revenue changed -39.5% year-over-year
- Net margin of -1106.7%
- P/E ratio of -0.4
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, ALGS posted revenue growth of -39.5% and trades at a P/E of -0.4.
Aligos Therapeutics, Inc. Common Stock (ALGS)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -63.8x — earnings do not cover interest payments
Operating margin at -2033.4% — severe operating losses
Net margin at -1919.7% — losses exceed revenue (possible one-time charges)
Net income fell 273.3% vs the prior period.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
82
Headquarters
SOUTH SAN FRANCISCO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.